Current Metastatic Melanoma Treatment Patterns In Academic Oncology.

e20119 Background: Treatment options for metastatic melanoma have changed rapidly over the past few years. Little evidence on patient experiences and outcomes in routine academic practice is available. Methods: A retrospective database was created of melanoma patients treated at Duke University between 6/30/09-6/30/13. Patients were eligible they if were u003e=18 years, had unresectable/metastatic disease (stage IIIC/IV), and had u003e 6 months of follow-up data. Demographic, clinical, treatment, and adverse event data were abstracted from the clinical chart. Descriptive statistics were used to report on the study population and treatments. Results: 274 patients met the inclusion criteria. They were predominantly male (66%) and Caucasian (93%) with a median age of 62 years and good functional status (89% of ECOG 0 or 1). A majority weretreated with at least one line of therapy (65%); the most common 1st line therapies included ipilimumab (25%), IL-2 (15%), temozolomide (6%), and vemurafenib (6%). Prior to FDA app...